Clinical Trial Search

Primary: Percent Change From Baseline to Week 12 in the Inflammatory (Papules and Pustules) Lesion Counts on the Face — -60.84; -62.17 percentage change in lesion counts — p=0.5947

Primary: Global Acne Grading System Score — 32; 30.33; 21.67; 27.5 score on a scale

Primary: Safety (Number of Participants With Treatment Related Adverse Events) — 4; 1; 2; 2 Participants

Primary: Inflammatory Lesion Counts — -29.9; -26.7; -24.8; -26.8 lesions

Primary: Number of Inflammatory Lesions (Papules and Pustules) — 6; 3; 10; 0 Lesions

Primary: Number of Correct Responses to Questionnaire Items Immediately Before and After and Educational Lecture — 79; 79; 74; 79 participants

Primary: The Primary Endpoint of This Study is the Percent of Patients Who Achieved Clear (0) or Almost Clear (1) on IGA Scale at Week 16 — 78 percentage of participants — p=<0.008

Primary: Mean Change From Baseline in Total Lesion Count — -26.9 Lesions counted

Primary: Percentage Patients With Successful Outcome Investigator's Global Assessment (IGA) Score at Week 12, Intent to Treat (ITT) Population — 14.1; 15.4; 29.5; 16.4 Percentage…

Primary: The Change in Number of Facial Inflammatory Acne-related Lesions. — 46; 23.7 Lesions

Primary: Subject Reported Change From Baseline Scale — 0; 0; 7; 6 Participants

Primary: The Absolute Change From Baseline in the Inflammatory Lesion Count at Week 12. — 16.39; 12.74 Lesion Count

Primary: Number of Participants With Treatment RelatedAdverse Events — 10; 9; 0; 0 Participants

Primary: Absolute Change in the Inflammatory Lesion Counts on the Face — 30.1; 29.8; 15.4; 16.9 Lesions

Primary: Absolute Change in Inflammatory Lesion Counts — -7.7; -4.1; -11.2; -11.3 inflammatory acne lesions

Primary: Number of Participants With 0 to 4 Investigator's Global Assessment Score at Week 6 — 0; 0; 3; 3 Participants

Primary: Percentage of Participants Achieving an IGA Score of Clear or Almost Clear and a Score ≥2 Grades Less Than Baseline — 25.4; 14.7 percentage of participants

Primary: Inflammatory Lesion Count (Papules and Pustules) at Day 40 — 10.1; 8.9; 6.1; 9.4 lesion count — p== 0.158

Primary: Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA) — 18.4; 9.0 Percentage of participants

Primary: Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA) — 20.3; 6.5 Percentage of subjects

Primary: Change From Baseline in Facial Inflammatory Lesion Counts at Week 12 — -6.8; -7.4; -9.6 lesions — p=0.3757

Primary: Number of Participants Who Were a Success (Subject's Global Assessment of 'Clear' or 'Almost Clear') at Week 12 — 18 participants

Primary: Percentage of Participants Achieving an IGA Score of Clear or Almost Clear and a Score ≥2 Grades Less Than Baseline — 38.5; 11.5 percentage of participants

Primary: Investigator's Global Assessment (IGA) "Success" - Week 12 — 5; 3; 2; 6 Participants

Primary: Mean Change From Baseline to Week 12 in Global Acne Assessment Score (GAAS) — -0.86 score on a scale

Primary: Proportion of Patients With Moderate to Severe Hypopigmentation and Hyperpigmentation Assessed After Treatment — 0; 0 participants

Primary: Absolute Change in Lesion Counts (Total, Inflammatory, and Non-inflammatory) From Baseline to Week 12 — -16.8; -18.1; -18.9; -18.8 Lesion count — p=0.692

Primary: Level of IL-1β — 52.5; 361.2 pg/mg

Primary: Percentage of Patients With a Score of 0 (None) or 1 (Minimal) on the 5-point Global Acne Assessment Score (GAAS) — 29.9; 21.2 Percentage of Patients

Primary: Success Rate on the Investigator's Global Assessment — 37.9; 21.8; 26.7; 17.9 Percentage of participants